TG Therapeutics, Inc. — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. This is an annual filing, not a standalone fourth-quarter report. TG Therapeutics is a development-stage biopharmaceutical company; its lead programs target hematologic cancers, and it had no approved products or product sales.
Financial performance and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| License revenue | $19,048 | $0 |
| Research and development expense | $21.03 million | $0.33 million |
| General and administrative expense | $4.78 million | $0.55 million |
| Operating loss | $26.90 million | $0.88 million |
| Consolidated net loss | $26.18 million | $0.89 million |
| Net loss attributable to TG Therapeutics | $18.07 million | $0.85 million |
| Cash used in operating activities | $5.19 million | $0.09 million |
| Cash and cash equivalents at year-end | $16.46 million | $9.75 million |
- The $2 million Ildong upfront sublicense payment was received in 2012, but recognized as revenue over the agreement term; $1.98 million remained deferred at year-end. The filing reports $330,000 of related foreign withholding tax.
- R&D included a $16.58 million noncash stock charge associated with the ublituximab license. The company also recorded a $1.10 million noncash impairment of acquired in-process R&D.
- Financing activities provided $11.90 million, primarily from the 2011 private placement’s 2012 closings. The company issued preferred stock that converted to common stock and also issued warrants, creating dilution potential.
- Year-end current assets were $18.48 million, including $1.99 million of prepaid R&D; current liabilities were $2.22 million. Total liabilities were $6.52 million and total equity was $15.55 million.
- Debt included a $677,778 current ICON note, in default after the company missed its January 2012 balloon payment, plus $123,511 of accrued interest. The company said it was seeking a settlement or alternative arrangement. Long-term notes were carried at fair value of $2.48 million; their face amount plus accrued interest was approximately $17.73 million, with payments tied to cash flows from legacy products.
Business developments and changes
- Ublituximab (TG-1101): The company held exclusive worldwide development and commercialization rights except France and Belgium. U.S. single-agent and lenalidomide-combination Phase I/II studies began in 2012. In the small completed French Phase I/II study, 5 of 11 evaluable patients had a partial response at month four; these early results are not evidence of approval or established efficacy.
- TGR-1202: The FDA accepted its IND in December 2012; the first-in-human Phase I study began in January 2013. Initial dose escalation was ongoing. Management noted that human pharmacokinetic results could lead to changes or discontinuation of the program.
- Licensing and collaboration: Ildong received sublicense rights for South Korea and Southeast Asia and could owe up to $5 million in additional milestones plus royalties. Rhizen and TG agreed to collaborate on TGR-1202; TG paid $1 million and was responsible for development through Phase II, with further milestone, licensing and royalty obligations possible.
- Other programs: AST-915 development was discontinued after its Phase I trial failed its primary efficacy endpoint. AST-726 development plans remained under review; no decision had been made.
- Reported expenses rose sharply versus 2011 as the company began clinical development and incurred license-related stock expense. Comparisons are affected by the December 2011 reverse acquisition, so the periods are not fully comparable.
Outlook, risks and unusual items
- Management estimated year-end cash would fund operations for approximately 18 months from December 31, 2012, and stated that continued operations and development would require additional financing. The estimate depends on clinical trial timing and other assumptions; there is no assurance funding will be available on acceptable terms.
- Estimated costs to complete stated phases were less than $1 million for ublituximab Phase I, approximately $3 million for its Phase Ib/II work, and approximately $2 million for TGR-1202 Phase I. Estimated completion dates ranged from mid-2013 to mid-2014 and were expressly uncertain and financing-dependent.
- The company expected continued operating losses and rising development expenses; it had no product revenue and could not predict when, or whether, it would become profitable.
- Key risks include clinical and regulatory failure, patient enrollment and trial delays, reliance on licensors and single-source contract manufacturers, competition, patent disputes, and the need to build commercial capabilities. Ublituximab also faces potential third-party patent issues identified in the filing.
- Management reported ineffective disclosure and financial reporting controls due to inadequate segregation of duties, with accounting duties performed by the CFO. Hiring additional accounting personnel in 2013 was the planned remediation. The auditor gave an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- The company disclosed an immaterial correction to previously reported 2011 balance-sheet valuations, with no effect on prior-period operations or equity. It reported no material pending legal proceeding involving the company; a Hedrin joint-venture arbitration remained ongoing, and the company reported a 13% JV interest in 2011 with no later information available.
Important facts for investors to verify
- Current cash runway, subsequent financing, and whether operating cash use and trial spending tracked management’s estimates.
- Clinical progress, safety, efficacy, enrollment, and pharmacokinetic findings for ublituximab and TGR-1202 after the filing date.
- Status and terms of the defaulted ICON note, the fair-value notes, and any resolution or payment obligations.
- Potential dilution from outstanding warrants, restricted stock, and future equity financing, and the precise license, milestone, and royalty terms.
- Progress in remediating the material weakness in internal controls and any subsequent auditor or management findings.
- Current status of AST-726, the Hedrin arbitration, and any developments affecting the value of legacy assets or related notes.